ArticleThe EMBO journal1994
Human lupus anti-DNA autoantibodies undergo essentially primary V kappa gene rearrangements.
Article in The EMBO journal, 1994. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 75 citations in OpenAlex.
- Impaired B-cell tolerance checkpoints promote the development of autoimmune diseases and pathogenic autoantibodies.Immunological reviews · 2019Review
- High Affinity Antibodies against Influenza Characterize the Plasmablast Response in SLE Patients After Vaccination.PloS one · 2015Article
- B cell receptor light chain repertoires show signs of selection with differences between groups of healthy individuals and SLE patients.Molecular immunology · 2012Article
- The establishment of early B cell tolerance in humans: lessons from primary immunodeficiency diseases.Annals of the New York Academy of Sciences · 2011Review
- B cell receptor editing in tolerance and autoimmunity.Annals of the New York Academy of Sciences · 2011Review
- Autoreactive IgG memory antibodies in patients with systemic lupus erythematosus arise from nonreactive and polyreactive precursors.Proceedings of the National Academy of Sciences of the United States of America · 2008Article
- B cells in autoimmune diseases: insights from analyses of immunoglobulin variable (Ig V) gene usage.Autoimmunity reviews · 2007Review
- Subversion of B lymphocyte tolerance by hydralazine, a potential mechanism for drug-induced lupus.Proceedings of the National Academy of Sciences of the United States of America · 2007Article
- Persistent expression of autoantibodies in SLE patients in remission.The Journal of experimental medicine · 2006Article
- Differential expression patterns of recombination-activating genes in individual mature B cells in juvenile idiopathic arthritis.Annals of the rheumatic diseases · 2006Article
- Consequences of receptor editing at the lambda locus: multireactivity and light chain secretion.Proceedings of the National Academy of Sciences of the United States of America · 2006Article
- Impaired early B cell tolerance in patients with rheumatoid arthritis.The Journal of experimental medicine · 2005Article
- Defective B cell tolerance checkpoints in systemic lupus erythematosus.The Journal of experimental medicine · 2005Article
- Over-expression of TATA binding protein (TBP) and p53 and autoantibodies to these antigens are features of systemic sclerosis, systemic lupus erythematosus and overlap syndromes.Clinical and experimental immunology · 2004Article
- Abnormalities of B cell phenotype, immunoglobulin gene expression and the emergence of autoimmunity in Sjögren's syndrome.Arthritis research · 2002Review
- Molecular determinants of the human antibody response to HIV-1: implications for disease control.Journal of clinical immunology · 2001Article
- Immunoglobulin kappa chain receptor editing in systemic lupus erythematosus.The Journal of clinical investigation · 1998Article
- Lupus-specific antibodies reveal an altered pattern of somatic mutation.The Journal of clinical investigation · 1997Article
- Characterization of a germline Vk gene encoding cationic anti-DNA antibody and role of receptor editing for development of the autoantibody in patients with systemic lupus erythematosus.The Journal of clinical investigation · 1996Article
- Human autoantibodies and their genes.Applied biochemistry and biotechnologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We have recently characterized the heavy chain variable region (VH) genes expressed by a panel of human anti-DNA antibodies derived from four patients with systemic lupus erythematosus and expressing an idiotypic marker representative of a subset of pathogenic autoantibodies. Here, we have cloned and sequenced the kappa chain variable region genes (V kappa) of the clones whose VH genes had been previously analysed. All the V kappa genes utilized map to the 280 kb portion of the 3' end of the locus, suggesting that they represent essentially the products of primary rearrangements. This proximal clustering of the V kappa genes used contrasts with the broad distribution of immunization-induced human antibody V kappa genes over 1400 kb of the locus. In addition, lupus autoantibodies show no tendency to express the downstream junctional (J kappa) exons--another indication of infrequent secondary variable gene assembly. Since successive rearrangements may extinguish high-affinity recognition of self antigens, we propose that this bias in V kappa and J kappa expression reflects a low rate of secondary light chain rearrangements among lupus autoantibodies. We also postulate that the corrective mechanism capable of editing potentially aggressive, self-reactive antibodies in these patients may be deficient--a deficit that could be genetically determined and/or somatically acquired.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.